Of Synexus Clinical Research Limited, pursuant to Section 54(1) of the UK Modern Slavery Act 2015,
as approved by the Board of Directors in June 2020

The UK Modern Slavery Act 2015 (the “Act”) requires companies doing business in the UK to prepare and publish a statement of the steps, if any, they have taken to ensure that slavery and human trafficking is not taking place in the business or in the companies’ supply chains (Section 54 of the Act). Synexus Clinical Research Limited and its vendors are subject to this Act and are publishing this statement in compliance with the Act.

We, Synexus Clinical Research Limited and all affiliated Synexus companies (hereinafter “Synexus” and/or Accelerated Enrollment Solutions, “AES”), are committed to improving our practices to combat slavery and human trafficking. Although we operate in a services industry, in which the risk of such unacceptable practices is arguably reduced, we do of course buy goods as well as services from third parties. We also operate in a global environment, and as such it is important that our global best practices are maintained regardless of the cultures and customs of the countries from which we buy goods.

AES has adopted a Code of Conduct for employees and directors. As clearly explained in our employee Code of Conduct, AES is committed to legal and ethical behaviour, and to acting professionally and fairly in all business dealings and relationships. We seek to maintain high ethical standards and to comply with all applicable laws and regulations. We expect integrity in all that we do, including with respect to our relationships with vendors. With these things in mind we welcome the introduction of the Modern Slavery Act 2015 and respect its intentions.

AES is the world’s largest site network, with 180+ sites and 2,500 employees. We provide customers with access to more than 100 million patients in key clinical development markets including Europe, Africa, Asia and the Americas. AES offers biopharmaceutical and contract research organisations (CRO) an unmatched capacity to find the right patient for the right trial at the right time. Our global scale and world-class site network delivers unparalleled capability, including data-driven site selection and activation, combined with proven patient engagement and retention expertise across the U.S., Europe, Africa and Asia.

Our network of Dedicated Research Sites and Affiliated Sites allows customers to commission global studies through a single contract with AES providing access to more than 100 million patients from our global site footprint. Customers then benefit from improved speed and efficiency in the trial process, with high numbers of retained patients recruited from a smaller number of sites, but also the reassurance of high quality data.

Patients respond to our community focused advertising. We tell them about the clinical trial process so they can make an informed choice and remain engaged throughout. Throughout we focus first and foremost on patient care and safety. This is why AES continues to be the patient’s choice for clinical research, with a growing community of over 800,000 patients

We are committed to ensuring that there is no modern slavery or human trafficking in our supply chains or in any part of our business. Our selection of vendors is governed by the Code of Conduct mentioned above.

As part of our initiative to identify and mitigate risk we conduct due diligence prior to engaging with a vendor. The level and content of the due diligence depends on the vendor’s risk profile and proposed

Our Corporate Compliance Committee will assess any actual or suspected offence in connection with modern slavery and determine specific remedial actions. The Committee consists of senior executive leaders from Legal, Global Quality and Compliance, Human Resources, Finance and the operational departments.

We have in place systems to enable and protect whistle-blowers, which complement and strengthen our anti-slavery due diligence and monitoring processes.

To ensure a higher level of understanding of the risks of modern slavery and human trafficking in our supply chains and our business, we will provide general training to our staff.

As a company operating with strong commitment to high legal and ethical standards, we will continue to assess our business at all times. Any issues identified will be addressed promptly, and we are committed to combatting the use of any form of modern slavery at all levels of our supply chains.

This statement applies to the financial year ending 31 December 2019.

Riaan Van Tonder
Director of Synexus Clinical Research Limited
June 2020